October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer
Sep 15, 2024, 16:36

Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer

Eda Eylemer Mocan, Medical oncologist at Ankara university, shared a recent article by Daniel P. Petrylak on X:

TROPHY-U-01 Cohort 2
SG in Metastatic Urothelial Cancer

  • Cisplatin-Ineligible
  • Progressing after ICI
  • Med f/u 9.3 m, ORR 32%, DOR 5.6 m
  • Grade ≥3 AE 87% of pts
  • Neutropenia 34%
  • Anemia 24%
  • Fatigue 18%
  • Diarrhea 16%

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Authors: Daniel P. Petrylak, MD, Scott T. Tagawa, MD, Rohit K. Jain, MD, Manojkumar Bupathi, MD, Arjun Balar, MD,Arash Rezazadeh Kalebasty, MD, Saby George, MD and Petros Grivas, MD, PhD

Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer

Source: Eda Eylmer Mocan/X